Anti-PD-L1 antibodies and uses thereof

US9624298B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Horacio G. Nastri · Needham, US
• Christel Iffland · Cambridge, US
• Olivier Leger · Bonneville, FR
• Qi An · Nashua, US
• Mark J. Cartwright · Newton, US
• Sean D. McKenna · Duxbury, US

Key dates

• Filing date: Nov 21, 2012
• Grant date: Apr 18, 2017
• Expiry date: Apr 14, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.